Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 7/20 | 0.44 |
| ▸ | TSPO | P30536 | 2/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694139 | 0.92 | TSPO (0.42) | FABP4TSPOFABP3HCRTR1HCRTR2 | |
| SCHEMBL5864637 | 0.90 | FABP4 (0.43) | FABP4TSPOFABP3PLA2G2A | |
| SCHEMBL6688729 | 0.90 | TSPO (0.43) | FABP4TSPOHCRTR1HCRTR2HTR6 | |
| SCHEMBL416598 | 0.89 | TSPO (0.42) | FABP4TSPOHCRTR1HCRTR2 | |
| SCHEMBL17286656 | 0.87 | PLA2G2A (0.40) | HCRTR1HCRTR2PLA2G2A | |
| SCHEMBL12748229 | 0.86 | TSPO (0.44) | FABP4TSPO | |
| SCHEMBL12748236 | 0.86 | TSPO (0.44) | FABP4TSPO | |
| SCHEMBL480340 | 0.86 | TSPO (0.55) | TSPO | |
| SCHEMBL12748241 | 0.86 | TSPO (0.44) | FABP4TSPO | |
| SCHEMBL6696662 | 0.85 | PLA2G2A (0.45) | TSPOHTR6PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |